Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis.
At week 10, filgotinib 200mg met the primary end point with a significantly higher proportion of patients achieving clinical remission compared with placebo.
“Given the minimal adverse events, we recommend that curcumin be considered as an adjunct to mesalamine in the treatment of UC.”
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
Practice guidelines and recommendations of the American College of Gastroenterology (ACG) for the management of adults with ulcerative colitis (UC).
The FDA has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis.
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
At Week 14, 22% of patients achieved resolution of neutrophilic inflammation, defined as NHI ≤1 or RHI ≤3 plus Geboes subgrades 2B.0/3.0. In the 13 patients who achieved clinical remission and 32 patients who achieved symptomatic remission, 77% and 44%, respectively
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. ORLANDO – Treatment with…
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
